Research
Semaglutide dose-response: what the trials establish
Semaglutide's effects are dose-related within its studied range, but the trials establish efficacy at specific labeled doses (2.4 mg weekly for weight
Semaglutide's effects are dose-related within its studied range, but the trials establish efficacy at specific labeled doses (2.4 mg weekly for weight; 50 mg oral in OASIS 1), not below them. There is no randomized characterization of a sub-therapeutic 'microdose' dose-response for weight loss.
What the trials establish
Across the STEP program, higher studied doses produced greater weight loss up to the labeled maintenance dose, and OASIS 1 showed an oral 50 mg dose reaching ~15% weight loss. This is a dose-response relationship within the studied range — it is not license to assume the curve extends predictably down to a microdose.
SUSTAIN-6 and SELECT add the outcome dimension: cardiovascular benefit was demonstrated at the studied doses in specific populations. None of these outcomes have been shown for a fraction of the labeled dose.
The honest reading is that 'more studied dose, more effect' holds inside the trial range, while the below-label region — exactly where 'microdosing' operates — is uncharacterized by randomized evidence.
| Trial | Population | N | Result | Citation | Identifiers |
|---|---|---|---|---|---|
| STEP 1 | Adults with overweight/obesity, without diabetes | 1,961 | Mean weight change about -14.9% vs -2.4% placebo | Wilding JPH, et al. N Engl J Med 2021;384:989-1002 | NCT03548935 · PMID 33567185 · DOI |
| STEP 3 | Adults with overweight/obesity | 611 | About -16.0% with drug + IBT vs -5.7% placebo + IBT | Wadden TA, et al. JAMA 2021;325(14):1403-1413 | NCT03611582 · PMID 33625476 · DOI |
| SELECT | Adults with CVD and overweight/obesity, without diabetes | 17,604 | About 20% reduction in major adverse cardiovascular events | Lincoff AM, et al. N Engl J Med 2023;389:2221-2232 | NCT03574597 · PMID 37952131 · DOI |
| SUSTAIN-6 | Adults with type 2 diabetes at high CV risk | 3,297 | Reduced CV events vs placebo in type 2 diabetes | Marso SP, et al. N Engl J Med 2016;375(19):1834-1844 | NCT01720446 · PMID 27633186 · DOI |
| OASIS 1 | Adults with overweight/obesity, without diabetes | 667 | About -15.1% vs -2.4% placebo with the approved oral formulation | Knop FK, et al. Lancet 2023;402(10403):705-719 | NCT05035095 · PMID 37385278 · DOI |
Identifiers verified against ClinicalTrials.gov and PubMed. Machine-readable dataset: studies.json · studies.csv.
What remains unknown
Across this topic, the recurring gap is the same: the randomized evidence describes approved products at studied doses, while compounded and deliberately sub-therapeutic 'microdose' use sits outside it. This page marks that boundary rather than blurring it.
What the evidence shows
- The cited trials carry verified NCT, PMID, and DOI identifiers and studied approved products at labeled doses.
- Findings here reflect those trials' actual results and populations.
What the evidence does not show
- That a compounded or microdose version reproduces these results — it has not been studied.
- That approved-product evidence transfers automatically to compounded formulations.
Frequently asked questions
Does a lower semaglutide dose work proportionally?
Unproven below the labeled range. Dose-response is established only within studied doses.
What doses were studied?
2.4 mg weekly injectable (STEP), 50 mg oral (OASIS 1), and 0.5–1.0 mg in SUSTAIN-6.
Related: evidence database · research hub. Compounded medications are not FDA approved.
Not medical advice. This page is consumer education, not medical advice, and does not recommend a dose, product, or provider. Compounded medications are not FDA approved. Talk with a licensed clinician about your situation.